Metastatic prostate cancer remains incurable, why?

Liang Dong, Richard C. Zieren, Wei Xue, Theo M. de Reijke, Kenneth J. Pienta

Research output: Contribution to journalReview article

Abstract

Metastatic prostate cancer patients present in two ways—with already disseminated disease at the time of presentation or with disease recurrence after definitive local therapy. Androgen deprivation therapy is given as the most effective initial treatment to patients. However, after the initial response, almost all patients will eventually progress despite the low levels of testosterone. Disease at this stage is termed castration resistant prostate cancer (CRPC). Before 2010, the taxane docetaxel was the first and only life prolonging agent for metastatic CRPC (mCRPC). The last decade has witnessed robust progress in CRPC therapeutics development. Abiraterone, enzalutamide, apalutamide and sipuleucel-T have been evaluated as first- and second-line agents in mCRPC patients, while cabazitaxel was approved as a second-line treatment. Radium-223 dichloride was approved in symptomatic patients with bone metastases and no known visceral metastases pre- and post-docetaxel. However, despite significant advances, mCRPC remains a lethal disease. Both primary and acquired resistance have been observed in CRPC patients treated by these new agents. It could be solely cell intrinsic or it is possible that the clonal heterogeneity in treated tumors may result from the adaptive responses to the selective pressures within the tumor microenvironment. The aim of this review is to list current treatment agents of CRPC and summarize recent findings in therapeutic resistance mechanisms.

Original languageEnglish (US)
Pages (from-to)26-41
Number of pages16
JournalAsian Journal of Urology
Volume6
Issue number1
DOIs
StatePublished - Jan 2019

Fingerprint

docetaxel
Prostatic Neoplasms
Castration
Therapeutics
Neoplasm Metastasis
Radium
Tumor Microenvironment
Androgens
Testosterone
Bone and Bones
Recurrence
Neoplasms

Keywords

  • Drug resistance
  • Heterogeneity
  • Novel treatment
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Metastatic prostate cancer remains incurable, why? / Dong, Liang; Zieren, Richard C.; Xue, Wei; de Reijke, Theo M.; Pienta, Kenneth J.

In: Asian Journal of Urology, Vol. 6, No. 1, 01.2019, p. 26-41.

Research output: Contribution to journalReview article

Dong, Liang ; Zieren, Richard C. ; Xue, Wei ; de Reijke, Theo M. ; Pienta, Kenneth J. / Metastatic prostate cancer remains incurable, why?. In: Asian Journal of Urology. 2019 ; Vol. 6, No. 1. pp. 26-41.
@article{145bf21fd0084bbc86bb1cc8b3e72c27,
title = "Metastatic prostate cancer remains incurable, why?",
abstract = "Metastatic prostate cancer patients present in two ways—with already disseminated disease at the time of presentation or with disease recurrence after definitive local therapy. Androgen deprivation therapy is given as the most effective initial treatment to patients. However, after the initial response, almost all patients will eventually progress despite the low levels of testosterone. Disease at this stage is termed castration resistant prostate cancer (CRPC). Before 2010, the taxane docetaxel was the first and only life prolonging agent for metastatic CRPC (mCRPC). The last decade has witnessed robust progress in CRPC therapeutics development. Abiraterone, enzalutamide, apalutamide and sipuleucel-T have been evaluated as first- and second-line agents in mCRPC patients, while cabazitaxel was approved as a second-line treatment. Radium-223 dichloride was approved in symptomatic patients with bone metastases and no known visceral metastases pre- and post-docetaxel. However, despite significant advances, mCRPC remains a lethal disease. Both primary and acquired resistance have been observed in CRPC patients treated by these new agents. It could be solely cell intrinsic or it is possible that the clonal heterogeneity in treated tumors may result from the adaptive responses to the selective pressures within the tumor microenvironment. The aim of this review is to list current treatment agents of CRPC and summarize recent findings in therapeutic resistance mechanisms.",
keywords = "Drug resistance, Heterogeneity, Novel treatment, Prostate cancer",
author = "Liang Dong and Zieren, {Richard C.} and Wei Xue and {de Reijke}, {Theo M.} and Pienta, {Kenneth J.}",
year = "2019",
month = "1",
doi = "10.1016/j.ajur.2018.11.005",
language = "English (US)",
volume = "6",
pages = "26--41",
journal = "Asian Journal of Urology",
issn = "2214-3882",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "1",

}

TY - JOUR

T1 - Metastatic prostate cancer remains incurable, why?

AU - Dong, Liang

AU - Zieren, Richard C.

AU - Xue, Wei

AU - de Reijke, Theo M.

AU - Pienta, Kenneth J.

PY - 2019/1

Y1 - 2019/1

N2 - Metastatic prostate cancer patients present in two ways—with already disseminated disease at the time of presentation or with disease recurrence after definitive local therapy. Androgen deprivation therapy is given as the most effective initial treatment to patients. However, after the initial response, almost all patients will eventually progress despite the low levels of testosterone. Disease at this stage is termed castration resistant prostate cancer (CRPC). Before 2010, the taxane docetaxel was the first and only life prolonging agent for metastatic CRPC (mCRPC). The last decade has witnessed robust progress in CRPC therapeutics development. Abiraterone, enzalutamide, apalutamide and sipuleucel-T have been evaluated as first- and second-line agents in mCRPC patients, while cabazitaxel was approved as a second-line treatment. Radium-223 dichloride was approved in symptomatic patients with bone metastases and no known visceral metastases pre- and post-docetaxel. However, despite significant advances, mCRPC remains a lethal disease. Both primary and acquired resistance have been observed in CRPC patients treated by these new agents. It could be solely cell intrinsic or it is possible that the clonal heterogeneity in treated tumors may result from the adaptive responses to the selective pressures within the tumor microenvironment. The aim of this review is to list current treatment agents of CRPC and summarize recent findings in therapeutic resistance mechanisms.

AB - Metastatic prostate cancer patients present in two ways—with already disseminated disease at the time of presentation or with disease recurrence after definitive local therapy. Androgen deprivation therapy is given as the most effective initial treatment to patients. However, after the initial response, almost all patients will eventually progress despite the low levels of testosterone. Disease at this stage is termed castration resistant prostate cancer (CRPC). Before 2010, the taxane docetaxel was the first and only life prolonging agent for metastatic CRPC (mCRPC). The last decade has witnessed robust progress in CRPC therapeutics development. Abiraterone, enzalutamide, apalutamide and sipuleucel-T have been evaluated as first- and second-line agents in mCRPC patients, while cabazitaxel was approved as a second-line treatment. Radium-223 dichloride was approved in symptomatic patients with bone metastases and no known visceral metastases pre- and post-docetaxel. However, despite significant advances, mCRPC remains a lethal disease. Both primary and acquired resistance have been observed in CRPC patients treated by these new agents. It could be solely cell intrinsic or it is possible that the clonal heterogeneity in treated tumors may result from the adaptive responses to the selective pressures within the tumor microenvironment. The aim of this review is to list current treatment agents of CRPC and summarize recent findings in therapeutic resistance mechanisms.

KW - Drug resistance

KW - Heterogeneity

KW - Novel treatment

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85075827646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075827646&partnerID=8YFLogxK

U2 - 10.1016/j.ajur.2018.11.005

DO - 10.1016/j.ajur.2018.11.005

M3 - Review article

C2 - 30775246

AN - SCOPUS:85075827646

VL - 6

SP - 26

EP - 41

JO - Asian Journal of Urology

JF - Asian Journal of Urology

SN - 2214-3882

IS - 1

ER -